Midlands Therapeutics Review and Advisory Committee (MTRAC)

Latest Verdicts published (excerpts available for public view.  For members of subscriber CCGs, please login to view the full text):

March 2019: new guidance

• Tapentadol (prolonged release; PR) for the treatment of severe chronic pain

 

February 2019: new guidance

• Dequalinium chloride for the treatment of bacterial vaginosis
• Cariprazine for the treatment of schizophrenia

.

January 2019: new fulltext guidance

• Class review of ocular lubricants for the treatment of dry eye diseases

.

December 2018: new fulltext versions available:

• Triple component inhalers for the treatment of chronic obstructive pulmonary disease (COPD)
  • Extrafine beclometasone dipropionate 87 mcg, formoterol fumarate 5 mcg, and glycopyrronium bromide 9 mcg
  • Fluticasone furoate 92mcg, vilanterol trifenatate 22mcg, and umeclidinium  bromide 65mcg

• Acetylcysteine for the treatment of hypersecretion of mucus in respiratory disorders

 

October 2018: new guidance

• Class review of ocular lubricants for the treatment of dry eye diseases

 

September 2018: new guidance

• Triple component inhalers for the treatment of chronic obstructive pulmonary disease (COPD)
  • Extrafine beclometasone dipropionate 87 mcg, formoterol fumarate 5 mcg, and glycopyrronium bromide 9 mcg
  • Fluticasone furoate 92mcg, vilanterol trifenatate 22mcg, and umeclidinium  bromide 65mcg

• Acetylcysteine for the treatment of hypersecretion of mucus in respiratory disorders

.

June 2018: fulltext now available

• Drug Class review of non vitamin-K antagonist oral anticoagulants (NOACs) for the treatment and secondary prevention of venous thromboembolism
• Eluxadoline for the treatment of irritable bowel syndrome with diarrhoea (update)

.

March 2018: new guidance

• Drug Class review of non vitamin-K antagonist oral anticoagulants (NOACs) for the treatment and secondary prevention of venous thromboembolism